The pros and cons of interferons for oncolytic virotherapy

Geoffroy, Karen; Bourgeois-Daigneault, Marie-Claude

doi:10.1016/j.cytogfr.2020.07.002

Cited by 23 publications

(22 citation statements)

References 155 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apparently at odds with the traditional view of Type I IFNs as antiviral agents, an ensemble of recent studies have shown that Type I IFNs actively contribute to the induction of antitumor-specific responses also in the context of OV [ 281 ]. Indeed, Type I IFN signaling was shown to play a role in inducing inflammatory responses in B16 melanomas locally treated with oncolytic Newcastle disease virus combined with systemic CTLA4 blockade.…”

Section: Type I Ifns and Cancer Therapy: From Response To Resistancementioning

confidence: 99%

“…Indeed, Type I IFN signaling was shown to play a role in inducing inflammatory responses in B16 melanomas locally treated with oncolytic Newcastle disease virus combined with systemic CTLA4 blockade. Of interest, the antitumor effects of OV were appreciable also in distant (non-virally injected) tumors [ 281 ]. Similarly, the therapeutic activity of a Semliki Forest virus encoding IL-12 was reported to strongly rely on a vector-induced Type I IFN response in the host [ 282 ].…”

Section: Type I Ifns and Cancer Therapy: From Response To Resistancementioning

confidence: 99%

See 1 more Smart Citation

The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation

Musella

Galassi

Manduca

et al. 2021

Biology

View full text Add to dashboard Cite

Type I Interferons (IFNs) are key regulators of natural and therapy-induced host defense against viral infection and cancer. Several years of remarkable progress in the field of oncoimmunology have revealed the dual nature of these cytokines. Hence, Type I IFNs may trigger anti-tumoral responses, while leading immune dysfunction and disease progression. This dichotomy relies on the duration and intensity of the transduced signaling, the nature of the unleashed IFN stimulated genes, and the subset of responding cells. Here, we discuss the role of Type I IFNs in the evolving relationship between the host immune system and cancer, as we offer a view of the therapeutic strategies that exploit and require an intact Type I IFN signaling, and the role of these cytokines in inducing adaptive resistance. A deep understanding of the complex, yet highly regulated, network of Type I IFN triggered molecular pathways will help find a timely and immune“logical” way to exploit these cytokines for anticancer therapy.

show abstract

Section: Type I Ifns and Cancer Therapy: From Response To Resistancementioning

confidence: 99%

Section: Type I Ifns and Cancer Therapy: From Response To Resistancementioning

confidence: 99%

The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation

Musella

Galassi

Manduca

et al. 2021

Biology

View full text Add to dashboard Cite

show abstract

“…Type III IFN was discovered later (known as IFN-λ) and it was reported in 2003 for the first time ( 36 , 37 ). It includes four kinds of IFN-λ isoforms, namely IFN-λ1 or IL-28a, IFN-λ2 or IL-28b, IFN-λ3 or IL-29, and IFN-λ4 ( 38 – 40 ). Similarly, viruses can mediate the expression of type III IFNs in diverse cell types ( 41 – 43 ).…”

Section: Ifn Generation and Signals Transmissionmentioning

confidence: 99%

The gamble between oncolytic virus therapy and IFN

Tan

Wang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Various studies are being conducted on oncolytic virotherapy which one of the mechanisms is mediating interferon (IFN) production by it exerts antitumor effects. The antiviral effect of IFN itself has a negative impact on the inhibition of oncolytic virus or tumor eradication. Therefore, it is very critical to understand the mechanism of IFN regulation by oncolytic viruses, and to define its mechanism is of great significance for improving the antitumor effect of oncolytic viruses. This review focuses on the regulatory mechanisms of IFNs by various oncolytic viruses and their combination therapies. In addition, the exerting and the producing pathways of IFNs are briefly summarized, and some current issues are put forward.

show abstract

“…Together, these studies show that our gene transfer approach is a promising immunotherapy for melanoma ( Hunger et al, 2017 ; Medrano et al, 2017 ; Cerqueira et al, 2020 ). The use of non-replicating vectors may be an advantage for our approach since the delivery of IFNβ can be counterproductive for replicating OVs ( Cerqueira et al, 2020 ; Geoffroy and Bourgeois-Daigneault, 2020 ; Tessarollo et al, 2021 ). The results to date are encouraging and research will continue, with critical development using clinically relevant models, such as testing with patient-derived tumor samples, including PDO and immunological ex vivo models ( Strauss et al, 2018 ).…”

Section: Using Engineered Viruses For Cancer Immunotherapymentioning

confidence: 99%

Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma

Cerqueira

Antunes

Assis

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Melanoma is the deadliest type of skin cancer with steadily increasing incidence worldwide during the last few decades. In addition to its tumor associated antigens (TAAs), melanoma has a high mutation rate compared to other tumors, which promotes the appearance of tumor specific antigens (TSAs) as well as increased lymphocytic infiltration, inviting the use of therapeutic tools that evoke new or restore pre-existing immune responses. Innovative therapeutic proposals, such as immune checkpoint inhibitors (ICIs), have emerged as effective options for melanoma. However, a significant portion of these patients relapse and become refractory to treatment. Likewise, strategies using viral vectors, replicative or not, have garnered confidence and approval by different regulatory agencies around the world. It is possible that further success of immune therapies against melanoma will come from synergistic combinations of different approaches. In this review we outline molecular features inherent to melanoma and how this supports the use of viral oncolysis and immunotherapies when used as monotherapies or in combination.

show abstract

The pros and cons of interferons for oncolytic virotherapy

Cited by 23 publications

References 155 publications

The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation

The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation

The gamble between oncolytic virus therapy and IFN

Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma

Contact Info

Product

Resources

About